Explore the categories so you can find more about your search.

Categorie > Schizophrenia

Gene Related To Brain Development And Function Plays Causal Role In Schizophrenia Study Finds

Categorie : Schizophrenia
According to a new study conducted by researchers at Mount Sinai School of Medicine, variations of a gene related to brain development and function--OLIG2--may play a causal role in the development of schizophrenia, a hereditary psychiatric disorder with no known biological cause. The study is publi ...

read more According to a new study conducted by researchers at Mount Sinai School of Medicine, variations of a gene related to brain development and function--OLIG2--may play a causal role in the development of schizophrenia, a hereditary psychiatric disorder with no known biological cause. The study is publi read more Mon Aug 2006 Mon Aug 2006

Ranbaxy Receives Tentative Approval To Market Risperidone Oral Solution

Categorie : Schizophrenia
Ranbaxy Pharmaceuticals Inc.(RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL),announced today that RLL has received tentative approval from the U.S. Foodand Drug Administration to manufacture and market Risperidone OralSolution, 1 mg/mL. Risperidone Oral Solution is indicat ...

read more Ranbaxy Pharmaceuticals Inc.(RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL),announced today that RLL has received tentative approval from the U.S. Foodand Drug Administration to manufacture and market Risperidone OralSolution, 1 mg/mL. Risperidone Oral Solution is indicat read more Mon Aug 2006 Mon Aug 2006

Ranbaxy Receives Tentative Approval From Us FDA To Market Risperidone Oral Solution

Categorie : Schizophrenia
Ranbaxy Laboratories Limited (RLL) announced today that the Company has received tentative approval from the U.S. Food and Drug Administration (US FDA) to manufacture and market Risperidone Oral Solution, 1 mg/mL. Risperdal® (risperidone) is indicated for the treatment of schizophrenia. Total annual ...

read more Ranbaxy Laboratories Limited (RLL) announced today that the Company has received tentative approval from the U.S. Food and Drug Administration (US FDA) to manufacture and market Risperidone Oral Solution, 1 mg/mL. Risperdal® (risperidone) is indicated for the treatment of schizophrenia. Total annual read more Mon Aug 2006 Mon Aug 2006

Spectrum Pharmaceuticals Announces A License And Collaboration Agreement For Ozarelix With Nippon Kayaku For The Japanese Market

Categorie : Schizophrenia
SpectrumPharmaceuticals, Inc. (Nasdaq: SPPI) today announced that its licensor forozarelix, AEterna Zentaris, has entered into a licensing and collaborationagreement with Nippon Kayaku for the fourth generation luteinizinghormone-releasing hormone (LHRH) antagonist, ozarelix. Under the terms ofthe ...

read more SpectrumPharmaceuticals, Inc. (Nasdaq: SPPI) today announced that its licensor forozarelix, AEterna Zentaris, has entered into a licensing and collaborationagreement with Nippon Kayaku for the fourth generation luteinizinghormone-releasing hormone (LHRH) antagonist, ozarelix. Under the terms ofthe read more Mon Aug 2006 Mon Aug 2006

Association Between Famine And Schizophrenia May Yield Clues About Inherited Diseases And Conditions

Categorie : Schizophrenia
The higher risk of schizophrenia among offspring of expectant mothers living through famine could help us understand the genetic basis for that debilitating mental disorder, a group of researchers argue in a commentary piece in the August issue of JAMA. The finding also supports a theory of medical ...

read more The higher risk of schizophrenia among offspring of expectant mothers living through famine could help us understand the genetic basis for that debilitating mental disorder, a group of researchers argue in a commentary piece in the August issue of JAMA. The finding also supports a theory of medical read more Mon Aug 2006 Mon Aug 2006

Schizophrenia: The Bearded Lady Disease - New Book Offers Evidence That Mental Illness Caused By Bisexual Conflict And Gender Confusion

Categorie : Schizophrenia
Schizophrenia remains amystery for many patients and doctors, but in his new book Schizophrenia:The Bearded Lady Disease (now available through AuthorHouse), J. MichaelMahoney offers evidence for a theory that would not only explain the causeof this particular ailment, but the root cause of all fun ...

read more Schizophrenia remains amystery for many patients and doctors, but in his new book Schizophrenia:The Bearded Lady Disease (now available through AuthorHouse), J. MichaelMahoney offers evidence for a theory that would not only explain the causeof this particular ailment, but the root cause of all fun read more Mon Aug 2006 Mon Aug 2006

AstraZeneca Submits An NDA For Sustained Release Formulation SEROQUEL SR(TM) For The Treatment Of Schizophrenia

Categorie : Schizophrenia
AstraZeneca today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration for a sustained release (SR) once-daily formulation of SEROQUEL for the treatment of patients with schizophrenia. The clinical trials to support the US submission of SEROQUEL SRTM used a ...

read more AstraZeneca today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration for a sustained release (SR) once-daily formulation of SEROQUEL for the treatment of patients with schizophrenia. The clinical trials to support the US submission of SEROQUEL SRTM used a read more Mon Aug 2006 Mon Aug 2006

AstraZeneca Submits An NDA For Sustained Release Formulation Seroquel SRTM For The Treatment Of Schizophrenia

Categorie : Schizophrenia
AstraZeneca today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration for a sustained release (SR) once-daily formulation of SEROQUEL for the treatment of patients with schizophrenia. The clinical trials to support the US submission of SEROQUEL SRTM used ...

read more AstraZeneca today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration for a sustained release (SR) once-daily formulation of SEROQUEL for the treatment of patients with schizophrenia. The clinical trials to support the US submission of SEROQUEL SRTM used read more Mon Aug 2006 Mon Aug 2006

AstraZeneca Submits NDA For Sustained Release Formulation Of SEROQUEL(R) For Schizophrenia Treatment

Categorie : Schizophrenia
AstraZeneca (NYSE:AZN) today announced that it has submitted a New Drug Application (NDA)with the U.S. Food and Drug Administration (FDA) for a sustained releaseformulation of SEROQUEL(R) (quetiapine fumarate) - SEROQUEL(R) SR in thetreatment of patients with schizophrenia. SEROQUEL tablets, in the ...

read more AstraZeneca (NYSE:AZN) today announced that it has submitted a New Drug Application (NDA)with the U.S. Food and Drug Administration (FDA) for a sustained releaseformulation of SEROQUEL(R) (quetiapine fumarate) - SEROQUEL(R) SR in thetreatment of patients with schizophrenia. SEROQUEL tablets, in the read more Mon Aug 2006 Mon Aug 2006

Investigational Drug Paliperidone ER Significantly Delayed Symptom Recurrence In Clinical Study Of Patients With Schizophrenia

Categorie : Schizophrenia
Paliperidone extended-release (ER) tablets, an investigational, once-daily oral medication, maintained long-term symptom stability in patients with schizophrenia. Data from a multinational, multicenter phase III study were presented today at the Biennial Congress of the Collegium Internationale Neur ...

read more Paliperidone extended-release (ER) tablets, an investigational, once-daily oral medication, maintained long-term symptom stability in patients with schizophrenia. Data from a multinational, multicenter phase III study were presented today at the Biennial Congress of the Collegium Internationale Neur read more Mon Aug 2006 Mon Aug 2006

Most Effective Antipsychotic Drug Has Serious Health Consequences

Categorie : Schizophrenia
Patients who take clozapine, the most effective antipsychotic drug, have significantly higher rates of metabolic syndrome, according to a first-of-a-kind study by University of Rochester Medical Center researchers.Metabolic syndrome is a group of conditions that increase the risk for heart disease, ...

read more Patients who take clozapine, the most effective antipsychotic drug, have significantly higher rates of metabolic syndrome, according to a first-of-a-kind study by University of Rochester Medical Center researchers.Metabolic syndrome is a group of conditions that increase the risk for heart disease, read more Mon Aug 2006 Mon Aug 2006

APA Applauds Congressional Efforts To Promote Research And Education On Mental Illnesses, USA

Categorie : Schizophrenia
Arlington, Va. -The American Psychiatric Association (APA) applauds the efforts of U.S. Representative Sue Myrick (R-N.C.) who initiated an Energy and Commerce Subcommittee on Health hearing held today on mental health disorders, entitled "Mental Illness and Brain Disease: Dispelling Myths and Promo ...

read more Arlington, Va. -The American Psychiatric Association (APA) applauds the efforts of U.S. Representative Sue Myrick (R-N.C.) who initiated an Energy and Commerce Subcommittee on Health hearing held today on mental health disorders, entitled read more Mon Aug 2006 Mon Aug 2006

Our Grip On Reality Is Slim, Says UCL Scientist

Categorie : Schizophrenia
The neurological basis for poor witness statements and hallucinations has been found by scientists at UCL (University College London). In over a fifth of cases, people wrongly remembered whether they actually witnessed an event or just imagined it, according to a paper published in NeuroImage this w ...

read more The neurological basis for poor witness statements and hallucinations has been found by scientists at UCL (University College London). In over a fifth of cases, people wrongly remembered whether they actually witnessed an event or just imagined it, according to a paper published in NeuroImage this w read more Mon Aug 2006 Mon Aug 2006

Studies Suggest New Brain Protein May Help In Treating Schizophrenia, Insomnia And Anxiety

Categorie : Schizophrenia
A small protein in the brain that has only recently been discovered and, paradoxically, induces both profound wakefulness and a less anxious state, may represent a novel target for the treatment of psychotic behavior and schizophrenia, according to new research presented at the 6th International Con ...

read more A small protein in the brain that has only recently been discovered and, paradoxically, induces both profound wakefulness and a less anxious state, may represent a novel target for the treatment of psychotic behavior and schizophrenia, according to new research presented at the 6th International Con read more Mon Aug 2006 Mon Aug 2006

Altered Activity In Receptor Pair Points To Further Complexity In Schizophrenia Pathology

Categorie : Schizophrenia
Researchers at the University of Pennsylvania School of Medicine, in collaboration with scientists at the City University of New York, have identified a striking dysregulation in neuronal receptor activity in the postmortem brain tissue from patients with schizophrenia. By stimulating receptors in t ...

read more Researchers at the University of Pennsylvania School of Medicine, in collaboration with scientists at the City University of New York, have identified a striking dysregulation in neuronal receptor activity in the postmortem brain tissue from patients with schizophrenia. By stimulating receptors in t read more Mon Aug 2006 Mon Aug 2006

Child Abuse Can Cause Schizophrenia - Manchester Academic To Tell Conferences

Categorie : Schizophrenia
University of Manchester researcher Paul Hammersley is to tell two international conferences, in London and Madrid in June 2006, that child abuse can cause schizophrenia.The groundbreaking and highly contentious theory, co-presented by New Zealand clinical psychologist Dr John Read, has been describ ...

read more University of Manchester researcher Paul Hammersley is to tell two international conferences, in London and Madrid in June 2006, that child abuse can cause schizophrenia.The groundbreaking and highly contentious theory, co-presented by New Zealand clinical psychologist Dr John Read, has been describ read more Mon Aug 2006 Mon Aug 2006

Athenagen Announces Publication Of Results From A Proof-of-Concept Trial Of Its Novel Alpha-7 Nicotinic Receptor Agonist In Schizophrenia

Categorie : Schizophrenia
Athenagen, Inc., aprivately held biopharmaceutical company, reported today that its leadcompound, GTS-21, a novel, orally active alpha-7 nicotinic acetylcholine(nACh) receptor agonist, demonstrated cognition enhancement activity in aproof-of-concept study in patients with schizophrenia. The study wa ...

read more Athenagen, Inc., aprivately held biopharmaceutical company, reported today that its leadcompound, GTS-21, a novel, orally active alpha-7 nicotinic acetylcholine(nACh) receptor agonist, demonstrated cognition enhancement activity in aproof-of-concept study in patients with schizophrenia. The study wa read more Mon Aug 2006 Mon Aug 2006

Radiation Therapy Shown To Increase Survival In Certain Lung Cancer Patients

Categorie : Schizophrenia
Treating certain lung cancer patients with surgery followed by radiation therapy can improve their chances of long-term survival, according to a study of more than 7,000 patients. The results, which suggest the need to reconsider radiation therapy's role in treatment, are reported today in the Journ ...

read more Treating certain lung cancer patients with surgery followed by radiation therapy can improve their chances of long-term survival, according to a study of more than 7,000 patients. The results, which suggest the need to reconsider radiation therapy's role in treatment, are reported today in the Journ read more Mon Aug 2006 Mon Aug 2006

Transcription Factor Protein's Role In Cell Death, Neurodegeneration And Schizophrenia

Categorie : Schizophrenia
Researchers at the University of Pennsylvania School of Medicine discovered that a protein called Elk-1 interacts with mitochondria, the energy storehouse of a cell, suggesting that this protein - typically active in the nucleus -- could play a role in cell death and mitochondria-related diseases su ...

read more Researchers at the University of Pennsylvania School of Medicine discovered that a protein called Elk-1 interacts with mitochondria, the energy storehouse of a cell, suggesting that this protein - typically active in the nucleus -- could play a role in cell death and mitochondria-related diseases su read more Mon Aug 2006 Mon Aug 2006

Prescriptions Of Antipsychotic Drugs To Children, Adolescents Increased Fivefold Between 1993 And 2002, Study Finds

Categorie : Schizophrenia
Doctors in 2002 prescribed antipsychotic drugs to children and adolescents at five times the rate they did in 1993, according to a study published on Monday in the Archives of General Psychiatry, the New York Times reports. [click link for full article] ...

read more Doctors in 2002 prescribed antipsychotic drugs to children and adolescents at five times the rate they did in 1993, according to a study published on Monday in the Archives of General Psychiatry, the New York Times reports. [click link for full article] read more Mon Aug 2006 Mon Aug 2006

<<< previous | 1 | 2 | 3 | 4 next >>>



     


Custom Search